AbbVie edges higher as 3rd-qtr financials best estimates
US drugmaker AbbVie (NYSE: ABBV) has announced better than expected financial results for the third quarter of 2021, pushing the firm’s shares up 2.9% to $112.60 before the opening bell this morning.
AbbVie delivered third-quarter net revenues of $14.342 billion, an Increase of 11.2% on a generally accepted accounting principles (GAAP) basis, just exceeding analysts; forecasts of $14.3 billion; adjusted net revenues increased 11.3% on a reported basis and 10.8% operationally.
Earnings per share (EPS) was $1.78 on a GAAP Basis, an Increase of 38.0% Percent; Adjusted Diluted EPS of $3.33, an Increase of 17.7%. beating the Zacks Consensus Estimate of $3.23 per share. Net earnings attributable to AbbVie for the quarter were $3.18 billion, up 38% versus $2.31 billion in the like year-earlier quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze